bluebird bio Inc. (NASDAQ:BLUE) went down by -3.02% from its latest closing price compared to the recent 1-year high of $72.50. The company’s stock price has collected -2.52% of loss in the last five trading sessions. Press Release reported 3 hours ago that DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against bluebird bio, Inc. and Encourages Investors to Contact the Firm
Is It Worth Investing in bluebird bio Inc. (NASDAQ :BLUE) Right Now?
Plus, the 36-month beta value for BLUE is at 1.77. Opinions of the stock are interesting as 9 analysts out of 24 who provided ratings for bluebird bio Inc. declared the stock was a “buy,” while 1 rated the stock as “overweight,” 14 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $47.89, which is $17.9 above the current price. BLUE currently public float of 66.04M and currently shorts hold a 8.19% ratio of that float. Today, the average trading volume of BLUE was 2.37M shares.
BLUE’s Market Performance
BLUE stocks went down by -2.52% for the week, with a monthly jump of 5.16% and a quarterly performance of -32.47%, while its annual performance rate touched -27.98%. The volatility ratio for the week stands at 4.67% while the volatility levels for the past 30 days are set at 5.54% for bluebird bio Inc.. The simple moving average for the period of the last 20 days is -1.58% for BLUE stocks with a simple moving average of -39.26% for the last 200 days.
Analysts’ Opinion of BLUE
Many brokerage firms have already submitted their reports for BLUE stocks, with Mizuho repeating the rating for BLUE by listing it as a “Buy.” The predicted price for BLUE in the upcoming period, according to Mizuho is $69 based on the research report published on March 10th of the current year 2021.
JP Morgan, on the other hand, stated in their research note that they expect to see BLUE reach a price target of $39, previously predicting the price at $76. The rating they have provided for BLUE stocks is “Neutral” according to the report published on February 17th, 2021.
BLUE Trading at -13.82% from the 50-Day Moving Average
After a stumble in the market that brought BLUE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -58.40% of loss for the given period.
Volatility was left at 5.54%, however, over the last 30 days, the volatility rate increased by 4.67%, as shares surge +6.76% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -35.33% lower at present.
During the last 5 trading sessions, BLUE fell by -2.52%, which changed the moving average for the period of 200-days by -52.94% in comparison to the 20-day moving average, which settled at $30.74. In addition, bluebird bio Inc. saw -30.30% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at BLUE starting from Gregory Philip D, who sale 39 shares at the price of $29.58 back on Mar 02. After this action, Gregory Philip D now owns 46,907 shares of bluebird bio Inc., valued at $1,154 using the latest closing price.
Cole Jason, the Chief Operating and of bluebird bio Inc., sale 38 shares at $29.58 during a trade that took place back on Mar 02, which means that Cole Jason is holding 47,997 shares at $1,124 based on the most recent closing price.
Stock Fundamentals for BLUE
Current profitability levels for the company are sitting at:
- -251.07 for the present operating margin
- +90.13 for the gross margin
The net margin for bluebird bio Inc. stands at -246.75. The total capital return value is set at -41.63, while invested capital returns managed to touch -41.54. Equity return is now at value -43.60, with -33.60 for asset returns.
Based on bluebird bio Inc. (BLUE), the company’s capital structure generated 14.24 points at debt to equity in total, while total debt to capital is 12.47. Total debt to assets is 10.84, with long-term debt to equity ratio resting at 12.40. Finally, the long-term debt to capital ratio is 10.85.
When we switch over and look at the enterprise to sales, we see a ratio of 6.90, with the company’s debt to enterprise value settled at 0.11. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.97.